Young & Partners Pharmaceutical Executive Summit 2024: The Impact of Artificial Intelligence on the Creation of Medicines (Pharmaceutical Executive)
Pharmaceutical Executive shares Fred Hassan's and Najat Khan's comments made at the 2024 Young & Partners Pharmaceutical Executive Summit. https://www.pharmexec.com/view/young-partners-pharmaceutical-executive-summit-2024-impact-artificial-intelligence-creation-medicines
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading? (Pharmaceutical Executive)
Pharmaceutical Executive shares Peter Marks' comments made at the 2024 Young & Partners Pharmaceutical Executive Summit. https://www.pharmexec.com/view/young-partners-pharmaceutical-executive-summit-2024-brave-new-world-where-heading-
Industry Restructuring & Inorganic Growth Through an Era of Chronic Oversupply (World Chemical Forum Speech September 10, 2024)
Young & Partners shares their thoughts and analysis of the global oversupply and uncertainties that have impacted the chemical markets. The presentation addresses the era of chronic oversupply, strategic assessments, M&A market conditions, and Strategic and M&A alternatives.
Chemical Debt Financing Rebounds (ICIS Chemical Business September 6 – September 12, 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have rebounded chemical debt financings and the outlook for 2024.
Chemical M&A Retreats Further (ICIS Chemical Business August 31 – September 5, 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed chemical M&A and the outlook for 2024.
Chemical Financing Activity Mixed (ICIS Chemical Business May 31 – June 6, 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed chemical financing and the outlook for 2024.
Chemical M&A Market Retreats (ICIS Chemical Business May 17 – May 23, 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed M&A and the outlook for 2024.
Young & Partners Chemical Financing: Reflections on 2023 and Outlook (March 2024)
Proprietary data and analysis of chemical financing trends in 2023 and the current outlook.
Biopharma Industry Business Review and Outlook (Pharmaceutical Executive, March 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed the M&A, stock market and financing in 2023, and the outlook for 2024.
Biopharma Market Review and Outlook (Pharmaceutical Executive, October 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed the M&A, stock market and financing in the first half, and the outlook for 2023.